Differences in nephrotoxicity risk and renal effects among anti‐viral therapies against hepatitis B

Results are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection.To compare short and long-term renal effects in real-life settings and to determine risk factors for renal impairment during treatment.2221 treatment-naïve patients were enrolled. Among these, 895 (302 lamivudine, 27 telbivudine, 282 entecavir, 273 tenofovir and 11 adefovir initiated patients) had 'repeated measures' of creatinine...